News for Nuvation Bio Inc. (NUVB-WT)

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced it will host

Nuvation Bio Inc. (NUVB) will announce its Q2 2025 financial results and provide a business update on August 7, 2025. The conference call and webcast wi

PR NewswireVANCOUVER, BC, July 10, 2025 USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc.VANCOUVER, BC, July 10, 2025 /PRNewswire/

Nuvation Bio Inc. (NYSE:NUVB) is one of the 10 best healthcare penny stocks to buy according to analysts. JMP Securities analyst Silvan Tuerkcan maintained a “Market Outperform” rating on Nuvation’s stock on June 25. The analyst also kept the price target at $6.00 per share. Tuerkcan’s decision follows Nuvation’s detailed presentation of launch plans for […]

Key Highlights: Nuvation Bio's (NUVB) shares saw an 8% jump following significant insider buying activity. CEO David Hung notably increased his stake wit

On June 18, 2025, Stacy Markel, Chief People Officer at Nuvation Bio Inc, purchased 10,000 shares of the company (symbol: NUVB). Following this transaction, the

In recent developments, RBC Capital has maintained its "Outperform" rating for Nuvation Bio (NUVB). Despite the consistent rating, the price target has experien

RBC Capital has adjusted its price target for Nuvation Bio (NUVB), reducing it from $10 to $6, while maintaining an Outperform rating on the stock. This decisio

Read the latest analysis on Nuvation Bio stock. Solid financials, positive analyst sentiment, and insider buying support merits a Speculative Buy rating for risk-tolerant investors.

On June 2, 2025, JMP Securities reaffirmed its position on Nuvation Bio (NUVB) by reiterating a "Market Outperform" rating. Analyst Silvan Tuerkcan confirmed th

As May draws to a close, it's time to turn our attention to the FDA's upcoming slate of decisions. The following biotech companies are awaiting potential approvals in June 2025.

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that additio

Nuvation Bio (NUVB) to present new data on taletrectinib at ASCO 2025 Annual Meeting. Taletrectinib shows efficacy and safety in ROS1-positive NSCLC acr

Nuvation Bio Inc. (NYSE: NUVB), a global oncology company tackling some of the toughest challenges in cancer treatment, today announced that David Hung, M.D.,

Nuvation Bio Inc. (NYSE:NUVB) Q1 2025 Earnings Call May 7, 2025 4:30 PM ETCompany ParticipantsJ.R.

Release Date: May 07, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Nuvation Bio Inc

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NNUVB.N - Nuvation Bio IncQ1 2025 Nuvation Bio Inc Earnings Call and Business UpdateMay 07, 202

We recently published a list of Billionaire David Abrams’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Nuvation Bio Inc. (NYSE:NUVB) stands against other stock picks with huge upside potential. David Abrams founded Abrams Capital Management in 1999. Before forming the Boston-based investment firm, Abrams worked […]

We recently published a list of Billionaire David Abrams’ 10 Stock Picks with Huge Upside Potential. In this article, we are going to take a look at where Nuvation Bio Inc.